CVSG.L

CVS Group Plc
CVS Group plc - Block Listing Interim Review
12th July 2024, 06:00
TwitterFacebookLinkedIn
To continue viewing RNS, please confirm that you are a Private Investor*

* A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:

  1. Obtains access to the information in a personal capacity;
  2. Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
  3. Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
  4. Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
  5. Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
  6. Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
RNS Number : 0549W
CVS Group plc
12 July 2024
 

12 July 2024

 

CVS Group plc

("CVS" or the "Company")

 

Block Listing Interim Review

CVS, one of the UK's leading providers of integrated veterinary services, makes the following notification pursuant to Schedule Six of the AIM Rules for Companies regarding its existing block listing arrangements. References to securities are to the Company's ordinary shares of 0.2 pence each ("Ordinary Shares").

Name of the company:

CVS Group plc

 

Name of relevant scheme:

1.    CVS Group SAYE Plan; and

2.    CVS Long Term Incentive Plan*

 

Period of return:

From:

12 January 2024

To:

12 July 2024

Balance of unallotted securities under scheme(s) from previous return:

1.    392,455

2.    68,393

Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):

1.    Nil

2.    Nil

Less:  Number of securities issued / allotted under scheme(s) during period:

1.    48,148

2.    Nil

Equals: Balance under scheme(s) not yet issued / allotted at end of period:

1.    344,307

2.    68,393

Number and class of securities originally listed and the date of admission:

1.    350,000 Ordinary Shares admitted on 30 December 2021

2.    120,000 Ordinary Shares admitted on 15 May 2023

*Previously referred to as Long Term Incentive Plan 2017

 

Contacts:

CVS Group plc                                                                                                                                via Camarco

Richard Fairman, CEO

Scott Morrison, Company Secretary

 

Peel Hunt LLP (Nominated Adviser & Broker)                                                 +44 (0)20 7418 8900

Christopher Golden / James Steele / Andrew Clark / Lalit Bose

 

   Berenberg (Joint Broker)                                                                                          +44 (0)20 3207 7800

Toby Flaux / Ben Wright / Ciaran Walsh / Milo Bonser

 

Camarco (Financial PR)                                                                                             

Geoffrey Pelham-Lane                                                                                +44 (0)7733 124 226

Ginny Pulbrook                                                                                                     +44 (0)7961 315 138

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
BLRQKDBQCBKKPOD]]>
TwitterFacebookLinkedIn